Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
McKesson
Colorcon
Moodys

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR DEUTETRABENAZINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Deutetrabenazine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01795859 ↗ First Time Use of SD-809 in Huntington Disease Completed Teva Branded Pharmaceutical Products R&D, Inc. Phase 3 2013-08-05 The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
NCT01795859 ↗ First Time Use of SD-809 in Huntington Disease Completed Teva Pharmaceutical Industries Phase 3 2013-08-05 The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
NCT01897896 ↗ Alternatives for Reducing Chorea in Huntington Disease Completed Auspex Pharmaceuticals, Inc. Phase 3 2013-11-12 The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed in "Switch" participants as well as "Rollover" participants completing a randomized, double blind, placebo-controlled study of SD-809 ER.
NCT02195700 ↗ Aim to Reduce Movements in Tardive Dyskinesia Completed Auspex Pharmaceuticals, Inc. Phase 2/Phase 3 2014-06-01 The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Deutetrabenazine

Condition Name

Condition Name for Deutetrabenazine
Intervention Trials
Tourette Syndrome 4
Huntington Disease 3
Tardive Dyskinesia 3
Cerebral Palsy, Dyskinetic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Deutetrabenazine
Intervention Trials
Huntington Disease 5
Tourette Syndrome 4
Syndrome 4
Dyskinesias 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Deutetrabenazine

Trials by Country

Trials by Country for Deutetrabenazine
Location Trials
United States 189
Poland 7
Canada 7
Australia 4
Slovakia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Deutetrabenazine
Location Trials
Texas 10
Tennessee 10
Alabama 9
Missouri 9
Florida 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Deutetrabenazine

Clinical Trial Phase

Clinical Trial Phase for Deutetrabenazine
Clinical Trial Phase Trials
Phase 3 8
Phase 2/Phase 3 3
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Deutetrabenazine
Clinical Trial Phase Trials
Completed 8
Recruiting 5
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Deutetrabenazine

Sponsor Name

Sponsor Name for Deutetrabenazine
Sponsor Trials
Teva Branded Pharmaceutical Products R&D, Inc. 8
Teva Branded Pharmaceutical Products, R&D Inc. 6
Auspex Pharmaceuticals, Inc. 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Deutetrabenazine
Sponsor Trials
Industry 23
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKesson
McKinsey
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.